2 recruiting, 1 not yet recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Vericiguat tablet: new trials by email Literature Review of Vericiguat tablet trials Research Report on Vericiguat tablet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients Vericiguat tablet, Placebo - Heart Failure With Reduced Ejection Fraction (HFrEF) | Phase 4 | Not yet recruiting | National Institute of Cardiovascular Diseases, Pakistan | 500 | 2026-07-15 | 2026-07-13 |
| Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial Vericiguat tablet, Sacubitril / Valsartan - Decompensated Heart Failure | Phase 1 | Recruiting | Khawaja Danish Ali | 130 | 2026-01-01 | 2026-03-02 |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) Vericiguat tablet, Vericiguat suspension, Placebo tablet - Heart Failure, Left Ventricular Systolic Dysfunction | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 342 | 2023-05-31 | 2026-10-30 |
Heart Failure (3) · Cardiovascular Diseases (1) · Emergencies (1) · Ventricular Dysfunction, Left (1)
Khawaja Danish Ali (1) · Merck Sharp & Dohme LLC (1) · National Institute of Cardiovascular Diseases, Pakistan (1)
Belgium (1) · Brazil (1) · Canada (1) · Colombia (1) · Croatia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · Ireland (1) · Italy (1) · Malaysia (1) · Mexico (1) · Netherlands (1)